Biotech Values

[DewDiligence]

…the timing doesn't sit well with me. one would think the stock in 6 months without another generic approved would have to be 20% higher. then again from a big picture standpoint waiting 6 months to move the business forward to try and get 20% more for a modest sized offering, while taking even a small chance that teva gets approved and potentially killing any equity financing at a palatable price may have been what management was weighing.

I think the risk of a bear market for stocks in general was a bigger factor in the timing of MNTA’s financing than concerns about Teva’s Lovenox.